Xinhua Pharmaceutical, Unit Obtain Registration Certificates for Two Drugs in China
MT Newswires Live
Sep 16
Shandong Xinhua Pharmaceutical (HKG:0719) received the drug registration certificate for erectile dysfunction drug Sildenafil Citrate Orodispersible tablets from China's National Medical Products Administration, a Tuesday Hong Kong bourse filing said.
Shandong Zibo Xincat Pharmaceutical, a unit of the pharmaceutical firm, also obtained a registration certificate for its Ursodeoxycholic Acid Capsules, indicated for the treatment of gallbladder cholesterol stones, from the regulator, a separate filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.